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April 12, 2011:1634–9it would be of great help if the authors would provide data on how
many patients had angina or ischemia (positive functional study) in
patients with ZES or PES restenosis.
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Reply
We thank Dr. Kaneda for his comments regarding our paper (1).
Although zotarolimus- and paclitaxel-eluting stents showed sim-
ilar angiographic results, the rate of target lesion and target vessel
revascularization was lower in the zotarolimus-eluting stent group.
The discrepancy between angiographic parameters and clinical
revascularization was also noted in the earlier REALITY (Head-
to-Head Comparison Between Cypher and Taxus) trial comparing
sirolimus-eluting and paclitaxel-eluting stents, in which the sig-
nificant differences in several continuous angiographic variables
(in-stent minimal luminal diameter, percentage of diameter ste-
nosis, in-stent late loss, and in-stent late loss index) did not
translate into significant differences in in-lesion binary restenosis
or in target lesion revascularization (2).
Although we do not fully explain this discrepancy between angio-
graphic measures and clinical outcomes, a plausible mechanism is
probably multifactorial. First, it might be possible that an angio-
graphically measured critical threshold inducing clinically or ischemia-
driven revascularization could differ among the different stent plat-
forms, even with similar angiographic parameters. It raises important
questions about the value of angiographic surrogate endpoints as
predictors of clinical outcome, as suggested in the literature (3,4).
Second, some difference in the incidence of the aggressive form (i.e.,
proliferative or total type) of in-stent restenosis (1.9% with zotaroli-mus stents and 0.5% with paclitaxel stents), which make it more
difficult for the treating physician to perform repeat intervention, thereby
favoring conservative medical treatment, might influence the rate of
target-lesion revascularization. Last, as suggested in other studies (5,6),
endothelial function of the implanted vessel according to different types of
DES could be a possible explanation for this discrepancy.
In the ZEST (Comparison of the Efficacy and Safety of
Zotarolimus-Eluting Stent with Sirolimus-Eluting and PacliTaxel-
Eluting Stent for Coronary Lesions) trial, as already defined, all target
vessel (or target lesion) revascularization was considered to be isch-
emia driven and clinically indicated if associated with a positive
functional study results, a target vessel (or target lesion) diameter
stenosis of 50% based on quantitative coronary angiography with
ischemic symptoms or a target vessel (or target lesion) diameter
stenosis of 70% with or without documented ischemia.
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Cardiac Magnetic Resonance for
Risk Stratification of Patients
With Frequent Premature
Ventricular Contractions
The study by Aquaro et al. (1) reported that abnormalities of the
right ventricle (RV) detected by cardiac magnetic resonance (CMR)
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April 12, 2011:1634–9were a powerful risk stratifier for cardiac death, resuscitated cardiac
arrest, or appropriate implantable cardioverter-defibrillator shock in a
select population. There were 396 patients with frequent premature
ventricular contractions (PVCs [1,000 PVCs in 24 h]) of left bundle
branch block morphology with an inferior QRS axis, all of whom
were said to have normal 12-lead resting electrocardiogram, no family
history of sudden cardiac death (presumably premature sudden cardiac
death), and normal 2-dimensional echocardiograms. The CMR
abnormalities were present in 61 of the 396 patients.
A number of questions remain unanswered by this report. The
normal electrocardiogram was not defined. Does this mean that
none of these patients had T-wave inversion in the precordial leads
beyond V1? It is not stated whether the patients had clinically
nonsustained or sustained ventricular tachycardia with or without
hemodynamic compromise. We find it remarkable that all of
the 396 patients with the above characteristics had normal
2-dimensional echocardiograms even though 126 (32%) had right
ventricular abnormalities detected by CMR, including 43 with
minor right ventricular wall motion abnormalities and 25 with
major wall motion abnormalities (akinesia or bulging) by this
imaging modality. The CMR studies were evaluated by 2 inde-
pendent expert CMR investigators, but there is no mention if there
was similar evaluation of the echocardiograms by experts in
echocardiography. Were quantitative echo data applied to the RV
assessment (such as tricuspid annular plane systolic excursion,
tissue Doppler S’ velocity, fractional area change, or index of
myocardial performance) as recommended by the recent American
Society of Echocardiography guidelines on RV assessment (2)?
The investigators utilized CMR studies to assist in classifying
atients with ventricular tachycardia as to whether right ventricular
ardiomyopathy was present utilizing Task Force Criteria estab-
ished in 1994 (3). In that report, there were no criteria defined for
MR studies for the diagnosis of arrhythmogenic right ventricular
ysplasia/cardiomyopathy (ARVC/D) as this imaging technique
as too new to be evaluated by the Task Force. The recently
ublished guidelines for the diagnosis of ARVC/D should be used
o assess right ventricular abnormalities by CMR (4). These
uidelines do not recognize fatty infiltration. In addition, fatty
nfiltration alone without extensive fibrosis is not a biopsy criterion
or ARVC/D as suggested by the authors.
The message of this paper is that CMR abnormalities alone may
ermit risk stratification of these select patients. The researchers
o not clarify the anatomic views prescribed during the CMR
xamination. Since CMR is used typically as an adjunct to (and
fter) screening echocardiography, it seems more appropriate that
he results of this test are done with dedicated attention to the RV.
n this setting, echocardiography and CMR together are likely to
dd constructively to the diagnosis of ARVC/D, rather than CMR
lone, which may otherwise result in inappropriate diagnosis of
RVC/D (5).
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Reply
We thank Dr. Marcus and colleagues for their interest in our
report (1). In this real-life clinical study, we evaluated the prog-
nostic impact of right ventricular (RV) abnormalities by magnetic
resonance imaging (MRI) in patients with frequent ventricular
premature complexes with left bundle branch morphology.
We excluded patients with other risk factors for arrhythmogenic
right ventricular cardiomyopathy (ARVC): patients had normal
electrocardiogram (also excluding T-wave inversion beyond V1),
normal echocardiogram, and negative maximal exercise test. Pa-
tients with sustained ventricular tachycardia, or nonsustained
ventricular tachycardia and hemodynamic compromise, were ex-
cluded. Patients were enrolled from 2002 and 2005, and echocar-
diogram was performed, but not as prescribed by the recent
guidelines (2): tricuspid annular plane systolic excursion was
calculated in all patients, but tissue Doppler S= velocity, fractional
area change, and other indexes of global RV performance were not
evaluated. However, the majority of patients with RV abnormal-
ities had focal right ventricle involvement (fat or wall motion
abnormalities) and preserved global right ventricle function (aver-
age RV ejection fraction 59  10%); only 6 of them had mild RV
ysfunction (mean ejection fraction 43%). Thus, the evaluation of
egional right ventricle function was determinant for the prognosis.
Cine MRI images were acquired covering the entire right
entricle without gap from diaphragm to the outflow tract in axial
iews and from the right atrium to the cardiac apex in short-axis
iews. In the recent Task Force criteria, the diagnostic accuracy of
RI for the diagnosis of ARVC was evaluated in a population of
62 healthy controls and 44 probands. Probands had an average
V ejection fraction of 43%, suggesting a global RV dysfunction
nd a more advanced stage of ARVC than in our study (3). We
elieve that the main advantage of MRI over other techniques is its
igher accuracy for detecting regional RV abnormalities even when
he global right ventricle function is preserved. This was clinically
elevant because, as it was demonstrated, the risk of sudden death
ith this cardiomyopathy is significant also in the subclinical phase
hen the fibrofatty infiltration is focal and the function is globally
reserved (4). Taking into account the potential advantages of
RI for assessing regional RV abnormalities, we agree that MRI
hould be performed only after echocardiography and not as an
lternative test in the diagnostic work-flow of ARVC.
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